First Line Metastatic Breast Cancer Treatment (ESMERALDA)

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The efficacy of eribulin is now well known in metastatic breast cancer. Furthermore, a phase III combine study ( chemo + bev)in metastatic first line shown a gain in PFS with no extra toxicities.

It could be interesting to explore the combination of bev + eribulin in first line metastatic breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ARCAGY/ GINECO GROUP
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Age > 18 ans

• Patient with metastatic mammary adenocarcinoma

• Hormone receptors ER and PR positive or negative for HER 2 negative

Exclusion Criteria:

• Prior chemotherapy for metastatic disease

• Previous treatment with eribulin or bevacizumab

• Presence of symptomatic brain metastases or meningeal